Tandem Investment Advisors Inc. Raises Stock Holdings in Stryker Co. (NYSE:SYK)

Tandem Investment Advisors Inc. boosted its holdings in Stryker Co. (NYSE:SYK) by 8.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 266,041 shares of the medical technology company’s stock after purchasing an additional 20,199 shares during the quarter. Stryker makes up approximately 3.6% of Tandem Investment Advisors Inc.’s holdings, making the stock its 8th biggest position. Tandem Investment Advisors Inc.’s holdings in Stryker were worth $96,110,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Koshinski Asset Management Inc. bought a new position in shares of Stryker during the first quarter worth $795,000. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Stryker by 43.1% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 18,491 shares of the medical technology company’s stock worth $6,617,000 after purchasing an additional 5,565 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Stryker by 78.9% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock worth $45,260,000 after buying an additional 58,673 shares in the last quarter. M&G Plc purchased a new position in Stryker during the 1st quarter valued at approximately $11,534,000. Finally, OFI Invest Asset Management increased its stake in Stryker by 3,210.9% in the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock worth $1,062,000 after acquiring an additional 3,243 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In related news, VP M Kathryn Fink sold 7,347 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the completion of the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Stryker news, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,068 shares of company stock valued at $3,693,972. Company insiders own 5.90% of the company’s stock.

Stryker Trading Up 0.2 %

Shares of NYSE SYK opened at $369.83 on Friday. Stryker Co. has a twelve month low of $266.93 and a twelve month high of $376.04. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $360.91 and a two-hundred day simple moving average of $345.12. The firm has a market cap of $140.99 billion, a PE ratio of 39.64, a price-to-earnings-growth ratio of 2.78 and a beta of 0.91.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the company posted $2.46 earnings per share. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. Analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SYK has been the subject of a number of recent research reports. Citigroup boosted their target price on shares of Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Evercore ISI boosted their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Barclays increased their price target on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Stifel Nicolaus cut their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Finally, Royal Bank of Canada raised their target price on shares of Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.